GLP-1 Medications and Skin Health: What Emerging Research Shows

*This article is for informational and educational purposes only. It is not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved. Clinical research cited in this article was conducted using FDA-approved formulations. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication or treatment program.*

---

Most people starting a GLP-1 medication are focused on weight. But researchers are increasingly documenting something else happening alongside the weight changes: improvements in inflammatory skin conditions that some patients have managed for years without much success.

Psoriasis flares quieting down. Hidradenitis suppurativa lesions becoming less frequent and less severe. Skin inflammation markers dropping in bloodwork.

This is not a coincidence. GLP-1 receptors are found throughout the body, including in immune cells, and these medications appear to modulate the inflammatory pathways that drive many chronic skin conditions. The research is still early, but it is accumulating quickly, and it is worth understanding what it shows and where its limits are.

---

How GLP-1 Medications Interact with the Immune System

To understand why researchers are interested in GLP-1 medications and skin health, you need to understand what GLP-1 receptor agonists actually do beyond lowering blood sugar and appetite.

GLP-1 receptors exist not just in the pancreas and gut, where they were originally studied, but across many organ systems, including immune cells. When GLP-1 receptor agonists bind to these receptors, they can influence the behavior of those immune cells in ways that reduce inflammation.

A 2025 systematic review published in *Diseases* (PMID 40422559), which analyzed 51 studies examining the dermatological effects of GLP-1 receptor agonists, found that these medications reduce levels of key pro-inflammatory cytokines: specifically TNF-alpha, IL-17, and IL-6. They also appear to block NF-kappaB signaling, a central pathway that drives inflammation in many autoimmune and inflammatory conditions, including psoriasis.

These are the same cytokines that targeted biologic medications (like adalimumab or secukinumab) block in order to treat psoriasis. GLP-1 medications do not block them as specifically or as powerfully, but the overlap in mechanism explains why clinicians started noticing skin improvements in patients who began GLP-1 therapy for metabolic reasons.

The anti-inflammatory effects also show up in bloodwork. Studies have documented decreases in C-reactive protein (CRP) and IL-6, both systemic markers of inflammation, following GLP-1 treatment. For patients with inflammatory skin conditions, which are driven by systemic immune dysregulation, this broader anti-inflammatory profile matters.

---

GLP-1 Medications and Psoriasis: What Clinical Research Shows

Psoriasis is a chronic autoimmune skin condition that causes the immune system to attack healthy skin cells, producing the characteristic red, scaly plaques. It affects roughly 2 to 3 percent of adults globally. It also co-occurs with obesity and metabolic syndrome at much higher rates than in the general population, which is one reason psoriasis patients have ended up in GLP-1 treatment studies.

A Randomized Clinical Trial

The most important study to date is a 2025 open-label randomized clinical trial published in *Biomolecules* (PMID 39858442). The study enrolled obese patients with type 2 diabetes and psoriasis, assigning some to semaglutide treatment and others to a control group.

After 12 weeks, the semaglutide group showed significant improvement in psoriasis severity. The Psoriasis Area and Severity Index (PASI) score, the standard clinical measure of psoriasis severity, declined from an average of 21 to 10 in the semaglutide group. Quality of life also improved, with Dermatology Life Quality Index (DLQI) scores falling from 14 to 4.

The study also documented decreases in serum IL-6 and CRP in the treatment group, suggesting the improvement was driven in part by genuine immune modulation, not just secondary to weight loss.

A Case Report That Caught Attention

Earlier evidence came from a 2021 case report published in *Endocrinology, Diabetes and Metabolism Case Reports* (PMID 34463640), which described a patient with type 2 diabetes and severe psoriasis who was started on semaglutide. The authors called it "two birds, one stone": the medication simultaneously improved glycemic control and produced dramatic clearance of psoriatic lesions.

This case helped prompt the more rigorous trials that followed.

What a 2025 Review Concluded

A comprehensive 2025 review in the *European Journal of Clinical Pharmacology* (PMID 40835981) synthesized the growing body of evidence on GLP-1 receptor agonists and psoriasis management. The authors concluded that GLP-1 medications show "emerging therapeutic potential" in psoriasis, particularly for patients who have coexisting obesity or metabolic syndrome.

The review identified two mechanisms at work: indirect effects through weight reduction (which itself reduces systemic inflammation) and direct immunomodulatory effects via GLP-1 receptors on immune cells in psoriatic plaques. Notably, the direct effects appear distinct from weight loss, suggesting GLP-1 medications may offer some skin benefit even independent of how much weight a patient loses.

The review also noted important limitations: most studies are small, populations are heterogeneous, and concurrent treatments (such as biologics or topical steroids) complicate interpretation. Larger randomized controlled trials specifically designed to isolate GLP-1 effects on psoriasis are still needed.

---

GLP-1 Medications and Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a painful, recurring inflammatory skin condition characterized by boils and abscesses in areas where skin folds, such as the armpits, groin, and under the breasts. It is notoriously difficult to treat. It also disproportionately affects people with obesity and metabolic syndrome.

A 2024 systematic review published in the *Journal of Clinical Medicine* (PMID 39518431) analyzed 25 studies looking at GLP-1 receptor agonists for HS treatment. The findings were encouraging. In a prospective case series of 14 HS patients receiving liraglutide, Hurley staging (the standard severity metric for HS) improved from an average of 2.6 to 1.1 over three months. C-reactive protein levels fell significantly. In a semaglutide study with 30 obese HS patients, mean quality-of-life scores improved substantially.

The review concluded that GLP-1 receptor agonists show therapeutic promise for HS by addressing both the metabolic dysfunction and the inflammatory pathways central to the condition's development. The authors noted, however, that the evidence base remains preliminary and that rigorous long-term randomized trials are needed before GLP-1 medications can be formally recommended as HS treatments.

---

Separating the Weight Loss Effect from the Direct Drug Effect

One of the hardest questions in this research is how much of the skin benefit comes from GLP-1 medications themselves versus from the weight loss they produce.

The relationship between obesity and inflammatory skin conditions is well-established. Fat tissue is metabolically active and pro-inflammatory: it secretes cytokines, raises systemic inflammation, and exacerbates immune dysregulation. Weight loss, from any cause, typically improves inflammatory markers and can reduce psoriasis and HS severity through that mechanism alone.

The researchers studying GLP-1 medications and skin health have been trying to tease these apart. The 2025 *Biomolecules* RCT (PMID 39858442) found changes in serum cytokines that suggest direct immune modulation beyond weight loss. The 2025 European Journal review (PMID 40835981) concluded there appear to be direct effects on GLP-1 receptors expressed in psoriatic plaques, distinct from the indirect metabolic pathway.

The honest answer is that both are probably happening, and in real patients they are difficult to separate. If you have psoriasis or HS and you are being treated with a GLP-1 medication for weight management, any skin improvement you experience is likely some combination of reduced systemic inflammation from weight loss, direct immunomodulatory effects of the medication, and, if applicable, improvements in coexisting conditions like insulin resistance that also drive skin disease.

---

What This Does Not Mean

Research showing associations and early trial signals does not mean GLP-1 medications are a treatment for skin conditions. A few important clarifications:

GLP-1 medications are not a dermatological treatment. No regulatory body has approved any GLP-1 medication for psoriasis, HS, or any other skin condition. These are medications prescribed for blood sugar management and weight management. The skin findings are secondary observations, not indications.

Not everyone will see skin benefits. Many people on GLP-1 medications have psoriasis or HS and see no change in their skin conditions. The studies are small and the populations are selected (most involve patients with both obesity and the skin condition). The research does not support expecting skin improvement as a routine outcome.

GLP-1 medications have real side effects. The most common include nausea, vomiting, diarrhea, and constipation, particularly in the early weeks of treatment and during dose increases. More serious but rare risks include pancreatitis, gallbladder disease, and potential kidney effects from dehydration. Anyone starting GLP-1 therapy should review the full side effect profile with their prescribing provider.

The research on dermatological adverse effects is also real. The same 2025 systematic review in *Diseases* (PMID 40422559) that documented skin benefits also documented skin-related adverse effects from GLP-1 medications: injection-site reactions, pruritus, rashes, and rare cases of bullous pemphigoid. The well-known "Ozempic face" phenomenon, facial volume loss from rapid weight reduction, also involves the skin, though differently. GLP-1 medications have complex effects on the skin in both directions.

---

If You Have a Skin Condition and Are Considering GLP-1 Treatment

If you have psoriasis, HS, or another inflammatory skin condition and are also a candidate for GLP-1 therapy for weight management or metabolic health, the emerging research is worth discussing with your dermatologist and prescribing provider together.

The conversation might include:

• Your current skin treatment regimen and how it might interact with GLP-1 therapy
• Whether your skin condition has a metabolic or obesity-related component that weight management might address
• What signs to monitor during treatment
• Whether any changes in skin status should prompt a medication adjustment

What this conversation should not include is starting a GLP-1 medication specifically and only for a skin condition. That is not what the research supports, and it is not a path a responsible provider should recommend based on current evidence.

The value of this research is that it gives patients and providers another reason to consider the full picture: that GLP-1 medications, when appropriate for metabolic reasons, may offer broader benefits than weight management alone, and that those benefits may extend to conditions that seem unrelated to weight but share underlying inflammatory mechanisms.

---

Limitations of the Current Evidence

It is worth being explicit about where the evidence stands.

Most studies in this area are small, ranging from case reports to trials with fewer than 50 participants. Study populations often overlap multiple conditions (obesity, type 2 diabetes, and a skin condition), making it difficult to generalize findings to people who have a skin condition without significant metabolic comorbidities.

Most studies use liraglutide or semaglutide; far less is known about tirzepatide's specific skin effects. Duration of follow-up in most studies is 3 to 12 months, which is insufficient to characterize long-term effects on chronic skin conditions.

The field needs larger, longer, placebo-controlled trials with pre-specified skin endpoints, in populations not necessarily selected for metabolic disease, before any firm conclusions about dermatological efficacy can be drawn.

---

The Bottom Line

The connection between GLP-1 medications and skin health is scientifically plausible and supported by early clinical evidence. Studies suggest these medications reduce key inflammatory cytokines, improve psoriasis severity in some patients, and show promise for hidradenitis suppurativa. But the evidence base is early, studies are small, and GLP-1 therapy is not a dermatological treatment.

For people who qualify for GLP-1 medication for weight management or metabolic health, this research adds useful context. It suggests that skin benefits may be a secondary gain for some patients, worth monitoring and discussing with their care team.

For people seeking GLP-1 medication primarily for a skin condition, the evidence does not yet support that path.

---

*Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.*

*Compounding Disclaimer: Compounded semaglutide and tirzepatide are not FDA-approved medications. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus). Compounded tirzepatide is not the same as, equivalent to, or interchangeable with FDA-approved tirzepatide products (Mounjaro or Zepbound).*

*Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.*

*Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC (DBA Prescriva) is a management services organization and does not practice medicine or make clinical decisions.*

*Brand Disclaimer: Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by these companies.*